Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1

Interventions

Cyclophosphamide 172Rituximab 157Specimen Handling 116Biopsy 93Magnetic Resonance Spectroscopy 90Vincristine 89Doxorubicin 83Prednisone 81fludarabine 70venetoclax 67obinutuzumab 62ibrutinib 55Lenalidomide 55Dexamethasone 55Cytarabine 49Methotrexate 46acalabrutinib 43Etoposide 41blinatumomab 40CT-P10 39Bendamustine Hydrochloride 37fludarabine phosphate 33Gemcitabine 33prednylidene 32Calcium Dobesilate 32deltacortene 31zanubrutinib 30pembrolizumab 29glofitamab 28Nivolumab 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Abatacept × Lymphoid × 90 days × Clear all
NCT07388563 2026-05-08

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Suspended
20 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡